Open Orphan PLC Value the Markets Webinar
February 10 2020 - 5:17AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
10 February 2020
10 February 2020
RNS REACH
Open Orphan Plc
("Open Orphan" or the "Company")
Value the Markets Webinar
Tuesday, 11 February 2020 at 7 pm
Open Orphan, the rapidly growing specialist CRO pharmaceutical
services company which has a focus on orphan drugs and is a world
leader in the provision of virology and vaccine challenge study
services, is pleased to announce that the Company will be hosting a
webinar for investors at 7pm on Tuesday 11(th) February. For those
wishing to join the event the participant details are below.
Join via Website: https://vtm.clickmeeting.com/orph
Join via Phone: +44 (20) 7048-4146
When prompted please provide the Participant's PIN code 159543#
followed by the # key
For further information please contact
+353 (0)1 644
Open Orphan plc 0007
Cathal Friel, Executive Chairman +44 (0)20 7347
Trevor Phillips, Chief Executive Officer 5350
Arden Partners plc (Nominated Adviser and
Joint Broker) +44 (0)20 7614
John Llewellyn-Lloyd / Benjamin Cryer 5900
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679
Anthony Farrell 6363
Camarco (Financial PR)
+44 (0)20 3757
Tom Huddart / Daniel Sherwen 4980
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor
communication service aimed at assisting listed and unlisted
(including AIM quoted) companies to distribute non-regulatory news
releases into the public domain. Information required to be
notified under the AIM Rules for Companies, Market Abuse Regulation
or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.
Notes to Editors:
Open Orphan is a rapidly growing European full pharmaceutical
services company with a focus on orphan drug and specialist
services, comprising two commercial specialist CRO services
businesses (Venn and hVIVO) and a developing early stage orphan
drug genomics data platform business capturing valuable genetic
data from patient populations with specific diseases with
designated orphan drug status and incorporating AI tools. In June
2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings
plc in a reverse take-over and in January 2020 it completed the
Merger with hVIVO plc. Venn, as an integrated drug development
consultancy, offers CMC (chemistry, manufacturing and controls) ,
preclinical, phase I & II clinical trials design and execution.
hVIVO, is a world leader in the provision of viral challenge
studies, vaccine and viral laboratory services, supporting product
development for customers developing antivirals, vaccines and
respiratory therapeutics, all particularly relevant and topical in
the environment of heightened awareness of the Coronavirus in 2020.
The Merger with hVIVO created a European full pharma services
company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRATMMBTMTBBBIM
(END) Dow Jones Newswires
February 10, 2020 06:17 ET (11:17 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024